Rocket Pharmaceuticals, Inc. Increase Decrease In Operating Lease Liability
Rocket Pharmaceuticals, Inc. (RCKT) reported Increase Decrease In Operating Lease Liability of $120.00 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2023-11-07
- Rocket Pharmaceuticals, Inc. increase decrease in operating lease liability for the quarter ending 2023-09-30 was $18.00K.
- Rocket Pharmaceuticals, Inc. increase decrease in operating lease liability for the quarter ending 2023-06-30 was $5.00K.
- Rocket Pharmaceuticals, Inc. increase decrease in operating lease liability for the quarter ending 2023-03-31 was $97.00K.
- Rocket Pharmaceuticals, Inc. increase decrease in operating lease liability for the quarter ending 2022-09-30 was -$32.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month |
|---|---|---|---|
| 2023-09-30 | $18.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $23.00K derived: sum of 2 quarters · filed 2023-11-07 | $120.00K 10-Q · filed 2023-11-07 |
| 2023-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $102.00K 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $97.00K 10-Q · filed 2023-05-05 | ||
| 2022-09-30 | -$32.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$63.00K derived: sum of 2 quarters · filed 2023-11-07 | -$96.00K 10-Q · filed 2023-11-07 |
| 2022-06-30 | -$31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$64.00K 10-Q · filed 2023-08-09 | |
| 2022-03-31 | -$33.00K 10-Q · filed 2023-05-05 | ||
| 2021-09-30 | $17.00K 10-Q · filed 2022-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |